Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166478 · ClinicalTrials.gov registry record · Phase 2
Exisulind Prior to Radical Prostatectomy
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
NCT00166478: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00166478 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00166478, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
Study Summary
This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be followed for total of 2 months from the time of starting study drug.
Interventions
- DRUG Exisulind Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166478
The ClinicalTrials.gov registry entry for NCT00166478 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exisulind Therapy is the first listed.
NCT00166478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00166478 about?
NCT00166478 is a clinical study titled "Exisulind Prior to Radical Prostatectomy". This trial will compare no treatment to exisulind therapy. Patients enrolled on the treatment arm will begin treatment 4 weeks prior to the scheduled date of surgical removal of the prostate and will take 375 mg by mouth daily for the 4 weeks prior to radical prostatectomy. Participants will be foll...
What is the current status of trial NCT00166478?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2002-04. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00166478?
The interventions under investigation include: Exisulind Therapy (DRUG).
Who is sponsoring clinical trial NCT00166478?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.